Critical Appraisal of Epidemiological Studies and Clinical Trials

Critical Appraisal of Epidemiological Studies and Clinical Trials

Volumn , Issue , 2009, Pages 1-584

  Elwood, Mark ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Bias; Case control study; Cause and effect; Confounding; Intervention trials; Observational studies; Screening; Selection of subjects; Statistical methods; Study design

Indexed keywords

EID: 84922530185     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780198529552.001.0001     Document Type: Book

References (518)

1. Robins JM, Breslow NE, Greenland S. Estimation of the Mantel-Haenszel variance consistent with both sparse-data and large-strata limiting models. Biometrics 1986; 42: 311-323.
2. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
3. Wolff B. On estimating the relationship between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
4. Rothman KJ, Greenland S. Modern epidemiology Second ed. Philadelphia: Lippincott -Raven; 1998.
5. Shapiro S, Slone D, Hartz SC, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976; i: 272-275
6. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1: The analysis of case-control studies. Lyon: IARC Scientific Publication No 32; 1980.
7. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4 ed. Oxford: Blackwell Scientific; 2002.
8. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized, double-blind, controlled trial in bone-marrowtransplant recipients. N. Engl. J Med 1981; 305, 63-67.
9. McNemar Q. Note on the sampling of the difference between corrected proportions or percentages. Psychometrika 1947; 12: 153-157.
10. Collette HJA, Day NE, Rombach JJ, de Waard F. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet 1984; 1: 1224-1226.
11. Elwood JM. Maternal and environmental factors affecting twin births in Canadian cities. Br J Obstet Gynaecol 1978; 85: 351-358.
12. Armitage P. Test for linear trend in proportions and frequencies. Biometrics 1955; 11: 375-386.
13. Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. Am Stat Assoc J 1963; 58: 690-700.
14. Westerdahl J, Anderson H, Olsson H, Ingvar C. Reproducibility of a selfadministered questionnaire for assessment of melanoma risk. Int J Epidemiol 1996; 25(2):245-251.
15. Cohen J. A coefficient of agreement for nominal scales. Educ. Psychol. Meas. 1960; 20:27-46.
16. Fleiss JL, Cohen J, Everitt BS. Large sample standard errors of kappa and weighted kappa. Psychol Bull 1969; 72: 323-327.
17. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3 ed. New York: John Wiley & Sons; 2003.
18. Thompson WD, Walter SD. Variance and dissent. A reappraisal of the kappa coefficient. J Clin Epidemiol 1988; 41: 949-958.
19. Armstrong BK, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. Oxford: Oxford University Press; 1992.
20. Hughes E, Collins, J., Vandekerckhove, P. Clomiphene citrate vs. placebo for ovaluation induction in oligo-amenorrhoeic women. Cochrane Database of Systematic Reviews 1995; 2 (CD-ROM). (This review has since been updated)
21. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35(1):1-39.
22. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine Second ed. New York: Oxford University Press; 2000.
23. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. In:Klein G, Weinhouse S, editors. Advances in Cancer Research Volume 49. 49 ed. Orlando:Academic Press; 1987. 285-401.
24. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
26. Robins JM, Breslow NE, Greenland S. Estimation of the Mantel-Haenszel variance consistent with both sparse-data and large-strata limiting models. Biometrics 1986; 42: 311-323.
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
28. Wolff B. On estimating the relationship between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
29. Rothman KJ, Greenland S. Modern Epidemiology (2nd edn). Philadelphia, PA:Lippincott-Raven, 1998.
30. Shapiro S, Slone D, Hartz, SC. Anticonvulsants nad parental epilepsy in the development of birth defects. Lancet 1976; i: 272-275
31. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. 1: The Analysis of Case-Control Studies. Lyon: IARC Scientific Publication No. 32, 1980.
32. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research (4th edn). Oxford: Blackwell Scientific, 2002.
33. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized, double-blind, controlled trial in bonemarrow- transplant recipients. N Engl J Med 1981; 305: 63-67.
34. McNemar Q. Note on the sampling of the difference between corrected proportions or percentages. Psychometrika 1947; 12: 153-157.
35. Collette HJA, Day NE, Rombach JJ, de Waard F. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet 1984; i: 1224-1226.
36. Elwood JM. Maternal and environmental factors affecting twin births in Canadian cities. Br J Obstet Gynaecol 1978; 85: 351-358.
37. Armitage P. Test for linear trend in proportions and frequencies. Biometrics 1955; 11: 375-386.
38. Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. Am Stat Assoc J 1963; 58: 690-700.
39. Westerdahl J, Anderson H, Olsson H, Ingvar C. Reproducibility of a self-administered questionnaire for assessment of melanoma risk. Int J Epidemiol 1996; 25: 245-251.
40. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 37-46.
41. Fleiss JL, Cohen J, Everitt BS. Large sample standard errors of kappa and weighted kappa. Psychol Bull 1969; 72: 323-327.
42. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions (3rd edn). New York: John Wiley, 2003.
43. Thompson WD, Walter SD. Variance and dissent. A reappraisal of the kappa coefficient. J Clin Epidemiol 1988; 41: 949-958.
44. Armstrong BK, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. Oxford: Oxford University Press, 1992.
45. Hughes E, Collins J, Vanderkerckhove P. Clomiphene citrate vs. placebo for ovulation induction in oligo-amenorrhoeic women. Cochrane Database Syst Rev 1995; 2 (CD-ROM)
46. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977; 35: 1-39.
47. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis:Methods for Quantitative Synthesis in Medicine Second ed. New York: Oxford University Press, 2000.
48. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 1987; 49: 285-401.
49. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
50. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
51. Charlton A. Children's coughs related to parental smoking. BMJ 1984; 288: 1647-1649.
52. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research. (4th edn). Oxford: Blackwell Scientific, 2002.
53. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications, 1982.
54. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
55. Rothman KJ, Greenland S. Modern Epidemiology (2nd edn). Philadelphia, PA:Lippincott-Raven, 1998.
56. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103: 226-235.
57. Greenland S. A counterexample to the test-based principle of setting confidence limits. Am J Epidemiol 1984; 120: 4-7.
58. Lyon JL, Gardner JW, West DW, Stanish WM, Hebertson RM. Smoking and carcinoma in situ of the uterine cervix. Am J Public Health 1983; 73: 558-562.
59. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967; 20: 511-524.
60. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG. abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis 1978; 31: 201-306.
61. Saracci R. Asbestos and lung cancer: an analysis of the epidemiological evidence on the asbestos-smoking interaction. Int J Cancer 1977; 20: 323-331.
62. Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. Am Stat Assoc J 1963; 58: 690-700.
63. Elwood JM. Maternal and environmental factors affecting twin births in Canadian cities. Br J Obstet Gynaecol 1978; 85: 351-358.
64. McNemar Q. Note on the sampling of the difference between corrected proportions or percentages. Psychometrika 1947; 12: 153-157.
65. Elwood JM, Williamson C, Stapleton PJ. Malignant melanoma in relation to moles, pigmentation, and exposure to fluorescent and other lighting sources. Br J Cancer 1986; 53: 65-74.
66. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford: Oxford Scientific Publications, 1993.
67. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 332: 349-360.
68. Armitage P. Sequential Medical Trials (2nd edn). Oxford: Blackwell Scientific, 1975.
69. Blot WJ, Li J-Y, Taylor PR, et al. Nutrition intervention trials in Linxian, China:supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-1492.
70. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
71. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
72. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
73. Pocock SJ. Clinical Trials: A Practical Approach. Chichester: John Wiley, 1983.
74. Machin D, Day S, Green SB. Textbook of Clinical Trials (2nd edn). Chichester:John Wiley, 2006.
75. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions (3rd edn). New York: John Wiley, 2003.
76. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
77. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977; 35: 1-39.
78. Godolphin W, Elwood JM, Spinelli JJ. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer; a study of 583 patients. Int J Cancer 1981; 28: 667-683.
79. Cox DR. Regression models and life-tables. J R Statist Soc Series B 1972; 34: 187-220.
80. Daniels M, Hill AB. Chemotherapy of pulmonary tuberculosis in young adults. An analysis of the combined results of three Medical Research Council trials. BMJ 1952; 1: 1162-1168.
81. Winkelstein W. The first use of meta-analysis?. Am J Epidemiol 1998; 147: 717.
82. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 1. Lancet 1992; 339: 1-15.
83. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
84. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106.
85. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
86. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet 2004; 363: 1007-1016.
87. Greenland S, Sheppard AR, Kaune WT, Poole C, Kelsh MA. A pooled analysis of magnetic fields, wire codes, and childhood leukemia. Epidemiology 2000; 11: 624-634.
88. Higgins JPT, Green S (Eds). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005), 2005. Available online at:
89. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. Oxford: Nuffield Provincial Hospitals Trust, 1972.
90. Non-Random Reflections on Health Services Research: On The 25th Anniversary of Archie Cochrane's 'Effectiveness and Efficiency'. London: BMJ Publishing Group, 1997.
91. Antes G, Oxman AD. The Cochrane Collaboration in the 20th century. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care. Meta-analysis in Context (2nd edn). London: BMJ Publishing Group, 2001, pp. 447-458.
92. Volmink J, Siegfried N, Robertson K, Gulmezoglu AM. Research synthesis and dissemination as a bridge to knowledge management: the Cochrane Collaboration. Bull World Health Organiz 2004; 82: 778-783.
93. The Cochrane Collaboration. RevMan 4.2 User Guide (updated April 2004), 2004. Available online at:
94. The Cochrane Collaboration. Glossary of Terms in The Cochrane Collaboration (updated May 2005), 2005. Available online at:
95. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
96. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
97. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull 1979; 86: 638-641.
98. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
99. Egger M, Dickersin K, Davey Smith G. Problems and limitations in conducting systematic reviews. In Egger M, Davey Smith G, Altman DG (eds), Systematic Reviews in Health Care. Meta-analysis in Context (2nd edn). London: BMJ Publishing Group, 2001, pp. 43-68.
100. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine: selective reporting from studies sponsored by pharmaceutical industry:review of studies in new drug applications. BMJ 2003; 326: 1171-1173.
101. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341-1345.
102. Anonymous. Depressing research. Lancet 2004; 363: 1335.
103. Sampson M, Barrowman NJ, Moher D, et al. Should meta-analysts search Embase in addition to Medline?. J Clin Epidemiol 2003; 56: 943-955.
104. Montori VM, Wilczynski NL, Morgan D, Haynes RB. Optimal search strategies for retrieving systematic reviews from Medline: analytical survey. BMJ 2005; 330: 68.
105. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline:analytical survey. BMJ 2005; 330: 1179.
106. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
107. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331: 1169.
108. Shang A, Huwiler-Muntener K, Nartey L, et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet 2005; 366: 726-732.
109. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991; 44: 127-139.
110. Committee on Government Operations. Misused Science: The National Cancer Institute's Elimination of Mammography Guidelines for Women in their Forties. Washington: US Government Printing Office, 1994.
111. Elwood JM. Breast cancer screening in younger women; the need for evidence based medicine. NZ Med J 1995; 108: 239-241.
112. Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-1055.
113. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In Egger M, Davey Smith G, Altman DG (ed), Systematic Reviews in Health Care. Meta-analysis in Context (2nd edn). London: BMJ Publishing Group, 2001, pp. 189-208.
114. Chalmers TC. Problems induced by meta-analyses. Stat Med 1991; 10: 971-980.
115. Greenland S. Quality scores are useless and potentially misleading. Reply to 'Re: A critical look at some popular analytic methods'. Am J Epidemiol 1994; 140: 300-302.
116. Juni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In Egger M, Davey Smith G, Altman DG (ed), Systematic Reviews in Health Care. Metaanalysis in Context (2nd edn). London: BMJ Publishing Group, 2001, pp. 87-108.
117. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12.
118. Brouwers MC, Johnston ME, Charette ML, Hanna SE, Jadad AR, Browman GP. Evaluating the role of quality assessment of primary studies in systematic reviews of cancer practice guidelines. BMC Med Res Methodol 2005; 5: 8.
119. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den BH. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-327.
120. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
121. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998; 352: 609-613.
122. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-1475.
123. Glasziou PP, Woodward AJ, Mahon CM. Mammographic screening trials for women aged under 50. A quality assessment and meta-analysis. Med J Aust 1995; 162: 625-629.
124. Hill D, White V, Jolley D, Mapperson K. Self examination of the breast: is it beneficial? Meta-analysis of studies investigating breast self-examination and extent of disease in patients with breast cancer. BMJ 1988; 297: 271-275.
125. Johnson N, Barlow D, Lethaby A, Tavender E, Curr L, Garry R. Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials. BMJ 2005; 330: 1478.
126. Grady D, Rubin S, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
127. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA 1995; 273: 149-154.
128. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. Br J Surg 2002; 89: 714-730.
129. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 1994; 308: 367-372.
130. Elwood JM. Childhood leukemia and residential magnetic fields. Are pooled analyses more valid than the original studies?. Bioelectromagnetics 2006; 27: 112-118.
131. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997; 26 (Suppl 1):S6-S14.
132. Sheikh A, Hurwitz B, Cave J. Antibiotics for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2000; (2): CD001211.
133. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
134. Greenland S, Salvan A. Bias in the one-step method for pooling study results. Stat Med 1990; 9: 247-252.
135. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 1987; 49: 285-401.
136. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
137. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73: 198-203.
138. The Cochrane Collaboration. RevMan 4.2.8 software (released July 2005), 2005. Available online at:
139. Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer 1995; 62: 377-381.
140. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for Quantitative Synthesis in Medicine (2nd edn). New York: Oxford University Press, 2000.
141. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141-151.
142. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
143. ISIS-4 (Fourth International Study of Infarct Survival Collaborative Group). ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
144. Sterne JAC, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
145. Charig CR, Webb DR, Payne SR, Wickham JEA. Comparison of treatment of renal calculi by open surgery, percutaneous nephrolithotomy, and extracorporeal shockwave lithotripsy. BMJ 1986; 292: 879-882.
146. Charig CR. Confounding and Simpson's paradox: multiple regression would confound the clinicians. BMJ 1995; 310: 329.
147. Simpson EH. The interpretation of interaction in contingency tables. J R Statist Soc 1951; 2: 238-241.
148. Paffenbarger RS, Hale WE. Work activity and coronary heart mortality. N Engl J Med 1975; 292: 545-550.
149. Adish AA, Esrey SA, Gyorkos TW, Jean-Baptiste J, Rojhani A. Effect of consumption of food cooked in iron pots on iron status and growth of young children: a randomised trial. Lancet 1999; 353: 712-716.
150. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials:explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
151. Dodd JM, Hedayati H, Pearce E, Hotham N, Crowther CA. Rectal analgesia for the relief of perineal pain after childbirth: a randomised controlled trial of diclofenac suppositories. BJOG 2004; 111: 1059-1064.
152. Cook CC, Scannell TD, Lipsedge MS. Another trial that failed. Lancet 1988; i: 524-525.
153. English DR, Burton RC, Del Mar CB, Donovan RJ, Ireland PD, Emery G. Evaluation of aid to diagnosis of pigmented skin lesions in general practice: controlled trial randomised by practice. BMJ 2003; 327: 375-380.
154. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II: mortality results. Diabetes 1970; 19(Suppl.2): 785-830.
155. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038-1041.
156. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen- year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69: 349-355.
157. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996; 348: 992-996.
158. Ashby D. Can iron supplementation improve cognitive functioning?. Lancet 1996; 348: 973.
159. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632.
160. Labrie F, Candas B, DuPont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91.
161. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-318.
162. Boer R, Schroder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate 1999; 40: 130-134.
163. Elwood M. A misleading paper on prostate cancer screening. Prostate 2004; 61: 372.
164. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
165. International Agency for Research on Cancer. Cancer Incidence in Five Continents Vol. VIII. Lyon, France:International Agency for Research on Cancer, 2002.
166. Elwood JM, Gallagher RP, Davison J, Hill GB. Sunburn, suntan and the risk of cutaneous malignant melanoma:the Western Canada Melanoma Study. Br J Cancer 1985; 51: 543-549.
167. Lyon JL, Gardner JW, West DW, Stanish WM, Hebertson RM. Smoking and carcinoma in situ of the uterine cervix. Am J Public Health 1983; 73: 558-562.
168. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?. Am J Epidemiol 2004; 159: 229-231.
169. Elwood JM. Wood exposure and smoking: association with cancer of the nasal cavity and paranasal sinuses in British Columbia. Can Med Assoc J 1981; 124: 1573-1577.
170. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
171. Halvorsen I, Andersen A, Heyerdahl S. Girls with anorexia nervosa as young adults. Self-reported and parentreported emotional and behavioural problems compared with siblings. Eur Child Adolesc Psychiatry 2005; 14: 397-406.
172. Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology 2005; 64: 442-447.
173. Swerdlow AJ, De Stavola BL, Floderus B, et al. Risk factors for breast cancer at young ages in twins: an international population-based study. J Natl Cancer Inst 2002; 94: 1238-1246.
174. Carlsson S, Hammar N, Grill V, Kaprio J. Alcohol consumption and the incidence of type 2 diabetes: a 20-year follow-up of the Finnish twin cohort study. Diabetes Care 2003; 26: 2785-2790.
175. Cederlöf R, Jonsson E, Kaij L. Respiratory symptoms and 'angina pectoris' in twins with reference to smoking habits: an epidemiological study with mailed questionnaire. Arch Environ Health 1966; 13: 726-737.
176. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878-881.
177. Hulten K, Van Kappel AL, Winkvist A, et al. Carotenoids, alpha-tocopherols, and retinol in plasma and breast cancer risk in northern Sweden. Cancer Causes Control 2001; 12: 529-537.
178. Forsyth BW, Horwitz RI, Acampora D, et al. New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. JAMA 1989; 261: 2517-2524.
179. Elwood JM, Williamson C, Stapleton PJ. Malignant melanoma in relation to moles, pigmentation, and exposure to fluorescent and other lighting sources. Br J Cancer 1986; 53: 65-74.
180. Rothman KJ, Greenland S. Modern Epidemiology (2nd edn). Philadelphia, PA: Lippincott-Raven, 1998.
181. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford: Oxford Scientific Publications, 1993.
182. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-936.
183. Hingorani A, Humphries S. Nature's randomised trials. Lancet 2005; 366: 1906-1908.
184. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol 2003; 32: 1-22.
185. Brennan P. Commentary: Mendelian randomization and gene-environment interaction. Int J Epidemiol 2004; 33: 17-21.
186. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986; i: 507-508.
187. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Int J Epidemiol 1986; 33: 9 (reprinted from Lancet 1986; i: 507-508).
188. Brennan P, Hsu CC, Moullan N, et al. Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a Mendelian randomisation approach. Lancet 2005; 366: 1558-1560.
189. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates?. Nature 1981; 290: 201-208.
190. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
191. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
192. Duffield-Lillico AJ, Begg CB. Reflections on the landmark studies of beta-carotene supplementation. J Natl Cancer Inst 2004; 96: 1729-1731.
193. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
194. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
195. Petitti DB, Freedman DA. Invited commentary: how far can epidemiologists get with statistical adjustment?. Am J Epidemiol 2005; 162: 415-418.
196. Lawlor DA, Davey SG, Kundu D, Bruckdorfer KR, Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?. Lancet 2004; 363: 1724-1727.
197. Aitken JF, Elwood JM, Lowe JB, Firman DW, Balanda KP, Ring IT. A randomised trial of population screening for melanoma. J Med Screen 2002; 9: 33-37.
198. Longnecker MP, Newcomb PA, Mittendorf R, Greenberg ER, Clapp RW, Bogdan GF et al. Risk of breast cancer in relation to lifetime alcohol consumption. J Natl Cancer Inst 1995; 87: 923-929.
199. Longnecker MP. Alcohol consumption in relation to risk of breast cancer: metaanalysis and review. Cancer Causes Control 1994; 5: 73-82.
200. Hunter DJ, Spiegelman D, Adami H-O, et al. Cohort studies of fat intake and the risk of breast cancer: a pooled analysis. N Engl J Med 1996; 334: 356-361.
201. Holmes MD, Willett WC. Does diet affect breast cancer risk?. Breast Cancer Res 2004; 6: 170-178.
202. Schatzkin A, Piantadosi S, Miccozzi M, Bartee D. Alcohol consumption and breast cancer: a cross-national correlation study. Int J Epidemiol 1989; 18: 28-31.
203. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer:collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002; 87: 1234-1245.
204. Longnecker MP. Invited commentary: the Framingham results on alcohol and breast cancer. Am J Epidemiol 1999; 149: 102-104.
205. Horn-Ross PL, Canchola AJ, West DW, et al. Patterns of alcohol consumption and breast cancer risk in the California Teachers Study cohort. Cancer Epidemiol Biomarkers Prev 2004; 13: 405-411.
206. McDonald JA, Mandel MG, Marchbanks PA, et al. Alcohol exposure and breast cancer: results of the women's contraceptive and reproductive experiences study. Cancer Epidemiol Biomarkers Prev 2004; 13: 2106-2116.
207. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001; 286: 2143-2151.
208. Petri AL, Tjonneland A, Gamborg M, et al. Alcohol intake, type of beverage, and risk of breast cancer in pre- and postmenopausal women. Alcohol Clin Exp Res 2004; 28: 1084-1090.
209. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and post-menopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst 2005; 97: 1601-1608.
210. Dumitrescu RG, Shields PG. The etiology of alcohol-induced breast cancer. Alcohol 2005; 35: 213-225.
211. Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE. MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2004; 13: 2071-2077.
212. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7: 149-156.
213. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167-1170.
214. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164-1167.
215. Weiss NS, Szekely DR, Austin DF. Increasing incidence of endometrial cancer in the United States. N Engl J Med 1976; 294: 1259-1262.
216. Austin DF, Roe KM. The decreasing incidence of endometrial cancer: public health implications. Am J Public Health 1982; 72: 65-68.
217. Anonymous. Hormone replacement therapy and endometrial carcinoma. Lancet 1977; i:577-578.
218. Mack TM, Pike MC. Hormone replacement therapy and endometrial carcinoma. Lancet 1977; i: 1358.
219. Hulka BS, Grimson RC, Greenberg BG, et al. 'Alternative' controls in a case- control study of endometrial cancer and exogenous estrogen. Am J Epidemiol 1980; 112: 376-387.
220. Hulka BS. Links between hormone replacement therapy and neoplasia. Fertil Steril 1994; 62(6 Suppl 2): 168S-175S.
221. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003; 10: 113-132.
222. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-313.
223. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005; Jul 20 (3): CD004143.
224. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-881.
225. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005; 142: 855-860.
226. Miettinen OS. Components of the crude risk ratio. Am J Epidemiol 1972; 96: 168-172.
227. Sears MR, Greene JM, Willan AR, et al. Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: a longitudinal study. Lancet 2002; 360: 901-907.
228. Silva PA, Stanton W. From Child to Adult: The Dunedin Multidisciplinary Health and Development Study. New York: Oxford University Press, 1997.
229. Poulton R, Hancox RJ, Moffitt TE. The Dunedin Multidisciplinary Health and Development Study: 1972-2006. Int J Epidemiol 2006; in press.
230. Lucas A, Brooke OG, Morley R, Cole TJ, Bamford MF. Early diet of preterm infants and development of allergic or atopic disease: randomised prospective study. BMJ 1990; 300: 837-840.
231. Infante-Rivard C, Amre D, Gautrin D, Malo JL. Family size, day-care attendance, and breastfeeding in relation to the incidence of childhood asthma. Am J Epidemiol 2001; 153: 653-658.
232. Romieu I, Werneck G, Ruiz VS, White M, Hernandez M. Breastfeeding and asthma among Brazilian children. J Asthma 2000; 37: 575-583.
233. Takemura Y, Sakurai Y, Honjo S, et al. Relation between breastfeeding and the prevalence of asthma : the Tokorozawa Childhood Asthma and Pollinosis Study. Am J Epidemiol 2001; 154: 115-119.
234. Rust GS, Thompson CJ, Minor P, vis-Mitchell W, Holloway K, Murray V. Does breastfeeding protect children from asthma? Analysis of NHANES III survey data. J Natl Med Assoc 2001; 93: 139-148.
235. van Odijk J., Kull I, Borres MP, et al. Breastfeeding and allergic disease: a multidisciplinary review of the literature (1966-2001) on the mode of early feeding in infancy and its impact on later atopic manifestations. Allergy 2003; 58: 833-843.
236. Oddy WH, de Klerk NH, Sly PD, Holt PG. The effects of respiratory infections, atopy, and breastfeeding on childhood asthma. Eur Respir J 2002, 19: 899-905.
237. Oddy WH, Sherriff JL, de Klerk NH, et al. The relation of breastfeeding and body mass index to asthma and atopy in children: a prospective cohort study to age 6 years. Am J Public Health 2004; 94: 1531-1537.
238. Rothenbacher D, Weyermann M, Beermann C, Brenner H. Breastfeeding, soluble CD14 concentration in breast milk and risk of atopic dermatitis and asthma in early childhood: birth cohort study. Clin Exp Allergy 2005; 35: 1014-1021.
239. Gdalevich M, Mimouni D, Mimouni M. Breast-feeding and the risk of bronchial asthma in childhood: a systematic review with meta-analysis of prospective studies. J Pediatr 2001; 139: 261-266.
240. Gdalevich M, Mimouni D, David M, Mimouni M. Breast-feeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. J Am Acad Dermatol 2001; 45: 520-527.
241. Wright AL, Holberg CJ, Taussig LM, Martinez FD. Factors influencing the relation of infant feeding to asthma and recurrent wheeze in childhood. Thorax 2001; 56: 192-197.
242. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl 16): 4-32.
243. Akinbami LJ, Schoendorf KC. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics 2002; 110: 315-322.
244. Pearce N, Douwes J. The global epidemiology of asthma in children. Int J Tuberc Lung Dis 2006; 10: 125-132.
245. Peat JK, Allen J, Oddy W, Webb K. Breastfeeding and asthma: appraising the controversy. Pediatr Pulmonol 2003; 35: 331-334.
246. Sears MR, Taylor DR, Poulton R. Breastfeeding and asthma: appraising the controversy-a rebuttal. Pediatr Pulmonol 2003; 36: 366-368.
247. Friedman NJ, Zeiger RS. The role of breast-feeding in the development of allergies and asthma. J Allergy Clin Immunol 2005; 115: 1238-1248.
248. Wills-Karp M, Brandt D, Morrow AL. Understanding the origin of asthma and its relationship to breastfeeding. Adv Exp Med Biol 2004; 554: 171-191.
249. Kramer MS, Kakuma R. The optimal duration of exclusive breastfeeding: a systematic review. Adv Exp Med Biol 2004; 554: 63-77.
250. Burgess SW, Dakin CJ, O'Callaghan MJ. Breastfeeding does not increase the risk of asthma at 14 years. Pediatrics 2006; 117: e787-e792.
251. Keil T, Kulig M, Simpson A, et al. European birth cohort studies on asthma and atopic diseases. I: Comparison of study designs-a GALEN initiative. Allergy 2006; 61: 221-228.
252. Rose PW, Harnden A, Brueggemann AB, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 37-43.
253. Sheikh A, Hurwitz B, Cave J. Antibiotics for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2000; (2): CD001211.
254. Rose PW, Harnden A, Brueggemann AB, Perea R, Mant D. Antibiotics for acute infective conjunctivitis in children. Lancet 2005; 366: 1431.
255. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
256. Medicines and Healthcare Products Regulatory Agency. Antibiotic eye drops available over the counter (OTC). 8-6-2005.
257. Saha N. Antibiotics for acute infective conjunctivitis in children. Lancet 2005; 366: 1432.
258. Rose PW, Ziebland S, Harnden A, Mayon-White R, Mant D. Why do general practitioners prescribe antibiotics for acute infective conjunctivitis in children? Qualitative interviews with GPs and a questionnaire survey of parents and teachers. Fam Pract 2006; 23: 226-232.
259. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J Gen Pract 2005; 55: 962-964.
260. Rietveld RP, ter Riet G, Bindels PJ, Bink D, Sloos JH, van Weert HC. The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial. Br J Gen Pract 2005; 55: 924-930.
261. MRC (Medical Research Council) Vitamin Study Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-137.
262. Smithells RW, Sheppard S, Schorah CJ, et al. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child 1981; 56: 911-918.
263. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. BMJ 1981; 282: 1509-1511.
264. Armitage P. Sequential Medical Trials (2nd edn). Oxford: Blackwell Scientific, 1975.
265. MacCarthy PA, Dalrymple IJ, Duignan NM, et al. Recurrence rates of neural tube defects in Dublin maternity hospitals. Ir Med J 1983; 76: 78-79.
266. Elwood JM, Little J, Elwood JH. Epidemiology and Control of Neural Tube Defects. Oxford: Oxford University Press, 1992.
267. Oakley GP, Jr., Erickson JD, James LM, Mulinare J, Cordero JF. Prevention of folic acid-preventable spina bifida and anencephaly. Ciba Found Symp 1994; 181: 212-231.
268. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999; 341: 1485-1490.
269. Czeizel AE, Dudas I. Prevention of the first occurence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-1835.
270. Czeizel AE, Dudas I, Metneki J. Pregnancy outcomes in a randomised controlled trial of periconceptional multivitamin supplementation. Final report. Arch Gynecol Obstet 1994; 255: 131-139.
271. Bentley JR, Ferrini RL, Hill LL. American College of Preventive Medicine Public Policy Statement. Folic acid fortification of grain products in the U.S. to prevent neural tube defects. Am J Prev Med 1999; 16: 264-267.
272. Wald NJ, Bower C. Folic acid and the prevention of neural tube defects. BMJ 1995; 310: 1019-1020.
273. Wald NJ. Folic acid and the prevention of neural-tube defects. N Engl J Med 2004; 350: 101-103.
274. Bower C, de Klerk N, Milne E, et al. Plenty of evidence on mandatory folate fortification. Aust N Z J Public Health 2006; 30: 81-82.
275. Botto LD, Lisi A, Robert-Gnansia E, et al. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working?. BMJ 2005; 330: 571.
276. Oakley GP Jr, Bell KN, Weber MB. Recommendations for accelerating global action to prevent folic acid-preventable birth defects and other folate-deficiency diseases:meeting of experts. Defects Res A Clin Mol Teratol 2004; 70: 835-837.
277. Anonymous. Folic acid and neural tube defects. Lancet 1991; 338: 153-154.
278. Whitehead AJ, Gallagher P, Mills JL, et al. A genetic defect in 5,10 methylenetetra-hydrofolate reductase in neural tube defects. Q J Med 1995; 88: 763-766.
279. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000; 71: 121-138.
280. Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. Lancet 2004; 364: 1885-1895.
281. Rothenberg SP, da Costa MP, Sequeira JM, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004; 350: 134-142.
282. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C Semin Med Genet 2004; 125: 12-21.
283. US Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease. Nutr Clin Care 2003; 6: 102-107.
284. Strohle A, Wolters M, Hahn A. Folic acid and colorectal cancer prevention:molecular mechanisms and epidemiological evidence (Review). Int J Oncol 2005; 26: 1449-1464.
285. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
286. Anonymous. Combination pharmacotherapy for cardiovascular disease. Ann Intern Med 2005; 143: 593-599.
287. Saracci R, Kogevinas M, Bertazzi P-A, et al. Cancer mortality in workers exposed to chlorophenoxy herbicides and chlorophenols. Lancet 1991; 338: 1027-1032.
288. Checkoway H, Pearce NE, Kriebel D. Research Methods in Occupational Epidemiology (2nd edn). Oxford: Oxford University Press, 2004.
289. International Agency for Research on Cancer. Occupational exposures to chlorophenoxy herbicides. IARC Monogr Eval Carcinog Risk Chem Hum 1986; 41: 357-406.
290. Kogevinas M, Becher H, Benn T, et al. Cancer mortality in workers exposed to phenoxy herbicides, chlorophenols, and dioxins. An expanded and updated international cohort study. Am J Epidemiol 1997; 145: 1061-1075.
291. Kogevinas M, Saracci R, Winkelmann R, et al. Cancer incidence and mortality in women occupationally exposed to chlorophenoxy herbicides, chlorophenols, and dioxins. Cancer Causes Control 1993; 4: 547-553.
292. Vena J, Boffetta P, Becher H, et al. Exposure to dioxin and nonneoplastic mortality in the expanded IARC international cohort study of phenoxy herbicide and chlorophenol production workers and sprayers. Environ Health Perspect 1998; 106 (Suppl 2): 645-653.
293. Heacock H, Hertzman C, Demers PA, et al. Childhood cancer in the offspring of male sawmill workers occupationally exposed to chlorophenate fungicides. Environ Health Perspect 2000; 108: 499-503.
294. Zhu K, Levine RS, Brann EA, Hall HI, Caplan LS, Gnepp DR. Case-control study evaluating the homogeneity and heterogeneity of risk factors between sinonasal and nasopharyngeal cancers. Int J Cancer 2002; 99: 119-123.
295. Mirabelli MC, Hoppin JA, Tolbert PE, Herrick RF, Gnepp DR, Brann EA. Occupational exposure to chlorophenol and the risk of nasal and nasopharyngeal cancers among U.S. men aged 30 to 60. Am J Ind Med 2000; 37: 532-541.
296. Hoppin JA, Tolbert PE, Flanders WD, et al. Occupational risk factors for sarcoma subtypes. Epidemiology 1999; 10: 300-306.
297. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer?. Am J Epidemiol 2004; 159: 252-258.
298. Leclerc A, Martinez CM, Gerin M, Luce D, Brugere J. Sinonasal cancer and wood dust exposure: results from a case-control study. Am J Epidemiol 1994; 140: 340-349.
299. Fikree FF, Gray RH, Shah F. Can men be trusted? A comparison of pregnancy histories reported by husbands and wives. Am J Epidemiol 1993; 138: 237-242.
300. Schull WJ, Cobb S. The intrafamilial transmission of rheumatoid arthritis. III: The lack of support for a genetic hypothesis. J Chronic Dis 1969; 22: 217-222.
301. Carter CO, David PA, Laurence KM. A family study of major central nervous system malformations in South Wales. J Med Genet 1968; 5: 81-106.
302. Mandel EM, Rockette HE, Bluestone CD, Paradise JL, Nozza RJ. Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. N Engl J Med 1987; 316: 432-437.
303. Cantekin EI, McGuire TW, Griffith TL. Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA 1991; 266: 3309-3317.
304. Rennie D. The Cantekin affair. JAMA 1991; 266: 3333-3337.
305. Silverman WA. Where's the Evidence? Debates in Modern Medicine. Oxford: Oxford University Press, 1998.
306. Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC. Pulseddye laser treatment for inflammatory acne vulgaris: randomised controlled trial. Lancet 2003; 362: 1347-1352.
307. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; ii: 769-782.
308. Tucker JS, Hall MH, Howie PW, et al. Should obstetricians see women with normal pregnancies? A multicentre randomised controlled trial of routine antenatal care by general practitioners and midwives compared with shared care led by obstetricians. BMJ 1996; 312: 554-559.
309. Weatherley-Jones E, Nicholl JP, Thomas KJ, et al. A randomised, controlled, triple-blind trial of the efficacy of homeopathic treatment for chronic fatigue syndrome. J Psychosom Res 2004; 56: 189-197.
310. Burns KE, Chu MW, Novick RJ, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. JAMA 2005; 294: 342-350.
311. Royal College of General Practitioners. Oral Contraceptives and Health: An Interim Report from the Oral Contraception Study of the Royal College of General Practitioners. New York: Pitman Medical, 1974.
312. Vessey M, Doll R, Peto R, Johnson B, Wiggins P. A long-term follow-up study of women using different methods of contraception-an interim report. J Biomed Sci 1976; 8: 373-427.
313. Vessey MP. Some methodological problems in the investigation of rare adverse reactions to oral contraceptives. Am J Epidemiol 1971; 94: 202-209.
314. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
315. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet 2004; 363: 1007-1016.
316. Doll R, Hill AB. A study of the aetiology of carcinoma of the lung. BMJ 1952; ii:1271-1286.
317. Johannes CB. Interviewer effects in a cohort study: results from the Massachusetts Women's Health Study. Am J Epidemiol 1997; 146: 429-438.
318. Paul C, Skegg DCG, Spears GFS, Kaldor JM. Oral contraceptives and breast cancer: a national study. BMJ 1986; 293: 723-726.
319. Grayson DA, O'Toole BI, Marshall RP, et al. Interviewer effects on epidemiologic diagnosis of posttraumatic stress disorder. Am J Epidemiol 1996; 144: 589-597.
320. Westerdahl J, Anderson H, Olsson H, Ingvar C. Reproducibility of a selfadministered questionnaire for assessment of melanoma risk. Int J Epidemiol 1996; 25: 245-251.
321. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 37-46.
322. Fleiss JL. Statistical Methods for Rates and Proportions (2nd edn). New York: John Wiley, 1981.
323. Harlow SD, Linet MS. Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am J Epidemiol 1989; 129: 233-248.
324. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine (2nd edn). Boston, MA: Little Brown, 1991.
325. Brennan P, Silman A. Statistical methods for assessing observer variability in clinical measures. BMJ 1992; 304: 1491-1494.
326. Aitken JF, Youl P, Janda M, et al. Validity of self-reported skin screening histories. Am J Epidemiol 2004; 159: 1098-1105.
327. Wald NJ, Cuckle HS, Boreham J, et al. Antenatal screening in Oxford for fetal neural tube defects. Br J Obstet Gynaecol 1979; 86: 91-100.
328. Institute for Clinical Evaluative Sciences. The jargon decoder: interpreting diagnostic tests. If you expect me to be sensitive, then don't ask me to be so specific. Informed 1998; 4: 1-2.
329. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostatespecific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 2005; 294: 66-70.
330. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
331. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005; 353: 1773-1783.
332. Armstrong BK, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. Oxford: Oxford University Press, 1992.
333. Thompson WD, Walter SD. Variance and dissent. A reappraisal of the kappa coefficient. J Clin Epidemiol 1988; 41: 949-958.
334. Rothman KJ, Greenland S. Modern Epidemiology (2nd edn). Philadelphia, PA:Lippincott-Raven, 1998.
335. Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol 2004; 159: 308-317.
336. Slanetz PJ, Moore RH, Hulka CA, et al. Physicians' opinions on the delivery of mammographic screening services: immediate interpretation versus double reading. AJR Am J Roentgenol 1996; 167(2): 377-379.
337. Ellenberg JH, Nelson KB. Sample selection and the natural history of disease. Studies of febrile seizures. JAMA 1980; 243: 1337.
338. The Toronto Leukemia Study Group. Results of chemotherapy for unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results. Lancet 1986; i: 786-788.
339. Morris JN. Uses of Epidemiology (1st edn). Edinburgh: Livingstone, 1957.
340. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167-1170.
341. Hulka BS, Grimson RC, Greenberg BG, et al. 'Alternative' controls in a case- control study of endometrial cancer and exogenous estrogen. Am J Epidemiol 1980; 112(3): 376-387.
342. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol 2006; 163(3): 197-203.
343. Edwards P, Roberts I, Clarke M, et al. Increasing response rates to postal questionnaires: systematic review. BMJ 2002; 324: 1183.
344. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69: 349-355.
345. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.
346. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993; 85: 1644-1656.
347. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290(12):1624-1632.
348. Holmberg L, Anderson H. HABITS (Hormonal Replacement Therapy After Breast Cancer-Is It Safe?), a randomised comparison: trial stopped. Lancet 2004; 363: 453-455.
349. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194.
350. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
351. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001; 285: 1992-1995.
352. Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC. Pulseddye laser treatment for inflammatory acne vulgaris: randomised controlled trial. Lancet 2003; 362: 1347-1352.
353. Tucker JS, Hall MH, Howie PW, et al. Should obstetricians see women with normal pregnancies? A multicentre randomised controlled trial of routine antenatal care by general practitioners and midwives compared with shared care led by obstetricians. BMJ 1996; 312: 554-559.
354. Baird PA, Yee IML, Sadovnick AD. Population-based study of long-term outcomes after amniocentesis. Lancet 1994; 344: 1134-1136.
355. Key TJA, Thorogood M, Appleby PN, Burr ML. Dietary habits and mortality in 11000 vegetarians and health conscious people: results of a 17 year follow up. BMJ 1996; 313: 775-779.
356. Royal College of General Practitioners. Oral contraceptives and Health: An Interim Report from the Oral Contraception Study of the Royal College of General Practitioners. New York: Pitman Medical; 1974.
357. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 318: 96-100.
358. Vessey M, Doll R, Peto R, Johnson B, Wiggins P. A long-term follow-up study of women using different methods of contraception-an interim report. J Biomed Sci 1976; 8: 373-427.
359. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-191.
360. Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983; ii: 930-934.
361. Johansen C, Boice JD, Jr., McLaughlin JK, Olsen JH. Cellular telephones and cancer-a nationwide cohort study in Denmark. J Natl Cancer Inst 2001; 93: 203-207.
362. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
363. Muscat JE, Malkin MG, Thompson S, et al. Handheld cellular telephone use and risk of brain cancer. JAMA 2000; 284: 3001-3007.
364. Paul C, Skegg DCG, Spears GFS, Kaldor JM. Oral contraceptives and breast cancer: a national study. BMJ 1986; 293: 723-726.
365. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361: 195-200.
366. Stocks P, Karn MN. A co-operative study of the habits, home life, dietary and family histories of 450 cancer patients and of an equal number of control patients. Ann Eugen 1933; 5: 237-280.
367. Muirhead CR, Bingham D, Haylock RGE, O'Hagan JA, Goodill AA, Berridge GL et al. Follow up of mortality and incidence of cancer 1952-98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes. Occup Environ Med 2003; 60(3): 165-172.
368. Baverstock K. The 2003 NRPB report on UK nuclear-test veterans. Lancet 2003; 361(9371): 1759-1760.
369. Packer CN, Stewart-Brown S, Fowle SE. Damp housing and adult health: results from a lifestyle study in Worcester, England. J Epidemiol Community Health 1994; 48: 555-559.
370. Kojima M, Wakai K, Tokudome S, et al. Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: a prospective study. Am J Epidemiol 2005; 161(5):462-471.
371. Elwood JM, Little J, Elwood JH. Epidemiology and Control of Neural Tube Defects. Oxford: Oxford University Press, 1992.
372. Hibbard ED, Smithells RW. Folic acid metabolism and human embryopathy. Lancet 1965; 1: 1254-1256.
373. Smithells RW, Sheppard S, Schorah CJ. Vitamin deficiencies and neural tube defects. Arch Dis Child 1976; 51: 944-950.
374. Smithells RW, Sheppard S, Schorah CJ, et al. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child 1981; 56: 911-918.
375. MRC (Medical Research Council) Vitamin Study Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-137.
376. Foulkes WD, Brunet J-S, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 1996; 313: 716-721.
377. Ghebreyesus TA, Haile M, Witten KH, et al. Incidence of malaria among children living near dams in northern Ethiopia: community based incidence survey. BMJ 1999; 319: 663-666.
378. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998; 317: 1181-1184.
379. Silverman WA. Where's the Evidence? Debates in Modern Medicine. Oxford: Oxford University Press, 1998.
380. British Medical Journal. Fifty years of randomised controlled trials. BMJ 1998; 317: 1167-1248.
381. Doll R. Controlled trials: the 1948 watershed. BMJ 1998; 317: 1217-1220.
382. Yoshioka A. Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. BMJ 1998; 317: 1220-1223.
383. Fibiger J. Om Serumbehandlung af Difteri. Hospitalstidende 1898; 6: 309-325.
384. Chalmers I, Clarke M. Commentary: The 1944 patulin trial: the first properly controlled multicentre trial conducted under the aegis of the British Medical Research Council. Int J Epidemiol 2004; 33(2): 253-260.
385. McCord J. A thirty year follow-up of treatment effects. Am Psychol 1978; 33: 284-289.
386. ISIS-4 (Fourth International Study of Infarct Survival Collaborative Group). ISIS-4:A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
387. Hill JD, Hampton JR, Mitchell JRA. A randomised trial of home-versus-hospital management for patients with suspected myocardial infarction. Lancet 1978; i: 837-841.
388. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen- year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69: 349-355.
389. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
390. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979; 8: 7-20.
391. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322: 19-22.
392. Cook DJ. Randomized trials in single subjects: the N of 1 study. Psychopharmacol Bull 1996; 32: 363-367.
393. March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P. n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ 1994; 309: 1041-1046.
394. Nikles CJ, Clavarino AM, Del Mar CB. Using n-of-1 trials as a clinical tool to improve prescribing. Br J Gen Pract 2005; 55: 175-180.
395. Mahon JL, Laupacis A, Hodder RV, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 1999; 115: 38-48.
396. Adish AA, Esrey SA, Gyorkos TW, Jean-Baptiste J, Rojhani A. Effect of consumption of food cooked in iron pots on iron status and growth of young children: a randomised trial. Lancet 1999; 353: 712-716.
397. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ, Donner A. Methods in health service research. Evaluation of health interventions at area and organisation level. BMJ 1999; 319: 376-379.
398. English DR, Burton RC, Del Mar CB, Donovan RJ, Ireland PD, Emery G. Evaluation of aid to diagnosis of pigmented skin lesions in general practice: controlled trial randomised by practice. BMJ 2003; 327: 375-380.
399. Arnold FA, Dean HT, Jay P, Knutson JW. Effect of fluoridated public water supplies on dental caries prevalence. Tenth year of the Grand Rapids-Muskegon study. Public Health Rep 1956; 71: 652-658.
400. Farquhar JW, Fortmann SP, Maccoby N, et al. The Stanford Five-City Project:design and methods. Am J Epidemiol 1985; 122: 323-334.
401. Fortmann SP, Flora JA, Winkleby MA, Schooler C, Taylor CB, Farquhar JW. Community intervention trials: reflections on the Stanford Five-City Project experience. Am J Epidemiol 1995; 142: 576-586.
402. Soderstrom L, Woods WG, Bernstein M, Robison LL, Tuchman M, Lemieux B. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening. J Natl Cancer Inst 2005; 97: 1118-1124.
403. Bunker CB, Barnes JA, Mosteller F, (Eds.). Costs, Risks and Benefits of Surgery. New York: Oxford University Press, 1977.
404. Ruffin JM, Grizzle JE, Hightower NC, McHardy G, Shull H, Kirsner JB. A cooperative double-blind evaluation of gastric 'freezing' in the treatment of duodenal ulcer. N Engl J Med 1969; 281: 16-19.
405. Bagenal FS, Easton DF, Harris E, Chilvers CE, McElwain TJ. Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet 1990; 336: 606-610.
406. Smithells RW, Sheppard S, Wild J, Schorah CJ. Prevention of neural tube defect recurrences in Yorkshire: final report (Letter). Lancet 1989; ii(8661): 498-499.
407. Selikoff IJ, Churg J, Hammond EC. Asbestos exposure, smoking and neoplasia. JAMA 1968; 204: 106-112.
408. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986; i: 1392-1393.
409. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
410. Bingham S, Riboli E. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Natl Rev Cancer 2004; 4: 206-215.
411. Doll R, Hill AB. Mortality in relation to smoking: ten years' observations of British doctors. BMJ 1964; i: 1399-1410.
412. Doll R, Gray R, Hafner B, Peto R. Mortality in relation to smoking: 22 years' observations on female British doctors. BMJ 1980; i: 967-971.
413. Hennekens CH, Speizer FE, Rosner B, Bain CJ, Belanger C, Peto R. Use of permanent hair dyes and cancer among registered nurses. Lancet 1979; i: 1390-1393.
414. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-762.
415. Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Cambridge, MA: Harvard University Press, 1980.
416. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7: 7S-12S.
417. Kuh D, Hardy R, Langenberg C, Richards M, Wadsworth ME. Mortality in adults aged 26-54 years related to socioeconomic conditions in childhood and adulthood:post war birth cohort study. BMJ 2002; 325: 1076-1080.
418. Wadsworth MEJ. The Imprint of Time: Childhood, History, and Adult Life. Oxford:Oxford University Press, 1991.
419. Susser E, Terry MB. A conception-to-death cohort. Lancet 2003; 361: 797-798.
420. Barbour V. UK Biobank: a project in search of a protocol?. Lancet 2003; 361: 1734-1738.
421. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878-881.
422. Doll R, Hill AB. Smoking and carcinoma of the lung. Preliminary report. BMJ 1950; ii:739-748.
423. Doll R, Hill AB. A study of the aetiology of carcinoma of the lung. BMJ 1952; ii:1271-1286.
424. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976; ii: 1525-1536.
425. MacGregor JE, Moss SM, Parkin DM, Day NE. A case-control study of cervical cancer screening in north east Scotland. BMJ 1985; 290: 1543-1546.
426. Selby JV, Friedman GD, Quesenberry CP, Jr, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer: a case-control study. Ann Intern Med 1993; 118: 1-6.
427. Weiss NS, McKnight B, Stevens NG. Approaches to the analysis of case-control studies of the efficacy of screening for cancer. Am J Epidemiol 1992; 135: 817-823.
428. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996; 88: 17-23.
429. Fentiman IS, Cuzick J, Millis RR, Hayward JL. Which patients are cured of breast cancer?. BMJ 1984; 289: 1108-1111.
430. Taffler RJ. Forecasting company failure in the UK using discriminant analysis of financial ratio data. J R Statist Soc 1982; 145: 342-358.
431. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004; 159: 259-268.
432. Redelmeier DA, Tibshirani RJ. Association betweeen cellular-telephone calls and motor vehicle collisions. N Engl J Med 1997; 336: 453-458.
433. Pauletto P, Puato M, Caroli MG, et al. Blood pressure and atherogenic lipoprotein profiles of fish-diet and vegetarian villagers in Tanzania: the Lugalawa study. Lancet 1996; 348: 784-788.
434. Törnberg SA, Carstensen JM. Relationship between Quetelet's index and cancer of breast and female genital tract in 47 000 women followed for 25 years. Br J Cancer 1994; 69: 358-361.
435. Cartwright A. Health Surveys in Practice and in Potential: A Critical Review of their Scope and Methods. London: King Edward's Hospital Fund for London, 1983.
436. Abramson JH. Survey Methods in Community Medicine: Epidemiological Research, Programme Evaluation, Clinical Trials 5th edn. Edinburgh: Churchill Livingstone, 1999.
437. Aday LA, Cornelius LJ. Designing and Conducting Health Surveys: A Comprehensive Guide 3rd edn. San Francisco, CA: Jossey-Bass, 2006.
438. MacMahon B. Epidemiological evidence on the nature of Hodgkin's disease. Cancer 1957; 10: 1045-1054.
439. Glaser SL, Jarrett RF. The epidemiology of Hodgkin's disease. Baillieres Clin Haematol 1996; 9: 401-416.
440. Howe GR, Burch JD, Miller AB, et al. Artificial sweeteners and human bladder cancer. Lancet 1977; ii: 578-581.
441. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333: 1369-1373.
442. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164-1167.
443. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
444. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983.
445. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
446. Hill D, White V, Jolley D, Mapperson K. Self examination of the breast: is it beneficial? Meta-analysis of studies investigating breast self-examination and extent of disease in patients with breast cancer. BMJ 1988; 297: 271-275.
447. Elwood JM, Little J, Elwood JH. Epidemiology and Control of Neural Tube Defects. Oxford: Oxford University Press, 1992.
448. Hill AB. The environment and disease: association or causation?. Proc R Soc Med 1965; 58: 295-300.
449. Crumpton MJ. The Bernal Lecture 2004. Are low-frequency electromagnetic fields a health hazard?. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1223-1230.
450. Ahlbom IC, Cardis E, Green A, Linet M, Savitz D, Swerdlow A. Review of the epidemiologic literature on EMF and Health. Environ Health Perspect 2001; 109 (Suppl 6): 911-933.
451. Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. Lancet 2004; 364: 1885-1895.
452. Emanuel I, Sever LE. Questions concerning the possible association of potatoes and neural-tube defects, and an alternative hypothesis relating to maternal growth and development. Teratology 1973; 8: 325-332.
453. Miller AB, Lindsay J, Hill GB. Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 1976; 17: 602-612.
454. Sloan JH, Kellermann AL, Reay DT, et al. Handgun regulations, crime, assaults, and homocide. N Engl J Med 1988; 319: 1256-1262.
455. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979; 121: 1193-1203.
456. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 1990; 43: 891-905.
457. Sibbald B, Addington-Hall J, Brenneman D, Freeling P. Telephone versus postal surveys of general practitioners: methodological considerations. Br J Gen Pract 1994; 44: 297-300.
458. U.S Preventive Services Task Force. The Guide to Clinical Preventive Services 2005. Washington, DC: Agency for Healthcare Research and Quality, 2005.
459. Guyatt GH, Rennie D (eds). Users' Guide to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago, IL: JAMA & Archives Journals, American Medical Association, 2002.
460. Mettlin C, Smart CR. Breast cancer detection guidelines for women aged 40 to 49 years: rationale for the American Cancer Society reaffirmation of recommendations. CA Cancer J Clin 1994; 44: 248-255.
461. Elwood JM. Breast cancer screening in younger women: evidence and decision making. J Eval Clin Pract 1997; 3: 179-186.
462. Jatoi I, Baum M. American and European recommendations for screening mammography in younger women: a cultural divide?. BMJ 1993; 307: 1481-1483.
463. National Institutes of Health Consensus Development Conference. National Institutes of Health Consensus Development Statement: Breast Cancer Screening for Women ages 40-49: January 21-23, 1997. Washington: National Institutes of Health, 1997.
464. Begley S. The mammogram war. Newsweek [Feb 24], 55-59. 1997.
465. Smith R. Where is the wisdom...? BMJ 1991; 303: 798-799.
466. Naylor CD. Grey zones of clinical practice: some limits to evidence-based medicine. Lancet 1995; 345: 840-842.
467. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-233.
468. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
469. Armitage P. Trials and errors: the emergence of clinical statistics. J R Statist Soc Ser A 1983; 146: 321-334.
470. Wright AE, Morgan WP, Colebrook L, Dodgson RW. Observations on the pharmaco-therapy of pneumococcus infections. Lancet 1912; ii: 1701-1705.
471. Wright AE. The Unexpurgated Case Against Women's Suffrage. London: Constable, 1913.
472. Pearson ES. Karl Pearson: An Appreciation of Some Aspects of His Life and Work. Cambridge: Cambridge University Press, 1938.
473. Susser M. Judgment and causal inference: criteria in epidemiologic studies. Am J Epidemiol 1977; 105: 1-15.
474. Nachbar J, (Ed.). Vaccine Therapy: Its Administration, Value and Limitations. A Discussion Opened by Sir Almroth E. Wright, MD, FRS. London: Longmans, Green, 1910.
475. Hill AB. Principles of Medical Statistics. London: The Lancet Ltd, 1937.
476. Anonymous. Mathematics and medicine. Lancet 1937; i: 31.
477. Sackett DL, Haynes RB, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical medicine. Boston, MA: Little, Brown, 1985.
478. Rosenberg W, Donald A. Evidence-based medicine: an approach to clinical problem-solving. BMJ 1995; 310: 1122-1126.
479. Ellis J, Mulligan I, Rowe J, Sackett DL. Inpatient general medicine is evidence based. Lancet 1995; 346: 407-410.
480. Wu J. Could evidence-based medicine be a danger to progress? Lancet 2005; 366: 122.
481. Hammersley.M. Is the evidence-based practice movement doing more good than harm? Reflections on Iain Chalmers' case for research-based policy making and practice. Evid Policy 2005; 1: 85-100.
482. Yokota T, Kojima S, Yamauchi H, Hatori M. Evidence-based medicine in Japan. Lancet 2005; 366: 122.
483. Maynard A. Evidence-based medicine: an incomplete method for informing treatment choices. Lancet 1997; 349: 126-128.
484. Klein R. The NHS and the new scientism: solution or delusion?. Q J Med 1996; 89: 85-87.
485. Sackett DL, Rosenberg WMC. The need for evidence-based medicine. J R Soc Med 1995; 88: 620-624.
486. Swales J. Scientific basis of health services. Science and medical practice: the turning tide. J Health Serv Res Policy 1996; 1: 61-62.
487. Mitton C, Donaldson C. Priority Setting Toolkit: A Guide to the Use of Economics in Healthcare Decision Making. London: BMJ Publishing, 2004.
488. Peacock S, Ruta D, Mitton C, Donaldson C, Bate A, Murtagh M. Using economics to set pragmatic and ethical priorities. BMJ 2006; 332: 482-485.
489. Mitton C, Donaldson C. Twenty-five years of programme budgeting and marginal analysis in the health sector, 1974-1999. J Health Serv Res Policy 2001; 6: 239-248.
490. Hauck K, Smith PC, Goddard M. The Economics of Priority Setting for Health Care: A Literature Review. Washington, DC: Health, Nutrition, and Population Family (HNP) of the World Bank's Human Development Network, 2003.
491. Innvaer S, Vist G, Trommald M, Oxman A. Health policy-makers' perceptions of their use of evidence: a systematic review. J Health Serv Res Policy 2002; 7: 239-244.
492. Greenlick MR, Goldberg B, Lopes P, Tallon J. Health policy roundtable-view from the state legislature: translating research into policy. Health Serv Res 2005; 40: 337-346.
493. Dobrow MJ, Goel V, Upshur RE. Evidence-based health policy: context and utilisation. Soc Sci Med 2004; 58: 207-217.
494. Coote A, Allen J, Woodhead D. Finding Out What Works: Building Knowledge About Understanding Complex, Community-Based Initiatives. London: King's Fund, 2004.
495. Bowen S, Zwi AB. Pathways to 'evidence-informed' policy and practice: a framework for action. PLoS Med 2005; 2: e166.
496. Soderstrom L, Woods WG, Bernstein M, Robison LL, Tuchman M, Lemieux B. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening. J Natl Cancer Inst 2005; 97: 1118-1124.
497. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; ii: 769-782.
498. Yoshioka A. Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. BMJ 1998; 317: 1220-1223.
499. Mack TM, Pike MC. Hormone replacement therapy and endometrial carcinoma. Lancet 1977; i(8026): 1358.
500. Reidy A, Minassian DC, Joseph J, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ 1998; 316: 1643-1646.
501. Beral V, Fraser P, Carpenter L, Booth M, Brown A, Rose G. Mortality of employees of the Atomic Weapons Establishment, 1951-82. BMJ 1988; 297: 757-770.
502. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361: 195-200.
503. ISIS-4 (Fourth International Study of Infarct Survival Collaborative Group). ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
504. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77(2): 193-198.
505. ISIS-4 (Fourth International Study of Infarct Survival Collaborative Group). ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
506. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-454.
507. Edwards A, Elwyn G, Covey J, Matthews E, Pill R. Presenting risk information: a review of the effects of "framing" and other manipulations on patient outcomes. J Health Commun 2001; 6: 61-82.
508. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994; 309: 761-764.
509. Sarfati D, Howden-Chapman P, Woodward A, Salmond C. Does the frame affect the picture? A study into how attitudes to screening for cancer are affected by the way benefits are expressed. J Med Screen 1998; 5: 137-140.
510. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
511. Paffenbarger RS, Hale WE. Work activity and coronary heart mortality. N Engl J Med 1975; 292: 545-550.
512. Royal College of General Practitioners' Oral Contraception Study. Mortality among oral-contraceptive users. Royal College of General Practitioners' Oral Contraception Study. Lancet 1977; ii: 727-731.
513. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 318: 96-100.
514. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-191.
515. Elwood JM, Raman S, Mousseau G. Reproductive history in the mothers of anencephalics. J Chronic Dis 1978; 31: 473-481.
516. Pauletto P, Puato M, Caroli MG, et al. Blood pressure and atherogenic lipoprotein profiles of fish-diet and vegetarian villagers in Tanzania: the Lugalawa study. Lancet 1996; 348: 784-788.
517. Charlton A. Children's coughs related to parental smoking. BMJ 1984; 288: 1647-1649.
518. Sloan JH, Kellermann AL, Reay DT, et al. Handgun regulations, crime, assaults, and homocide. N Engl J Med 1988; 319: 1256-1262.